NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Ratko TA, Belinson SE, Brown HM, et al. Hematopoietic Stem-Cell Transplantation in the Pediatric Population [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Feb. (Comparative Effectiveness Reviews, No. 48.)
This publication is provided for historical reference only and the information may be out of date.
Appendix Table C1. Design, participant selection and enrollment: Ewing's tumors (MS Word, 50K)
Appendix Table C2. Participant characteristics:Treatment, Ewing's tumors (MS Word, 49K)
Appendix Table C3. Participant characteristics: Comparator, Ewing's tumors (MS Word, 45K)
Appendix Table C4. Treatment characteristics: Ewing's tumors (MS Word, 53K)
Appendix Table C5. Outcome assessment: Treatment, Ewing's tumors (MS Word, 45K)
Appendix Table C6. Outcome assessment: Comparator, Ewing's tumors (MS Word, 43K)
Appendix Table C7. Time to event outcomes: Treatment, Ewing's tumors (MS Word, 51K)
Appendix Table C8. Time to event outcomes: Comparator, Ewing's tumors (MS Word, 44K)
Appendix Table C9. Adverse events: Treatment, Ewing's tumors (MS Word, 48K)
Appendix Table C10. Adverse events: Comparator, Ewing's tumors (MS Word, 43K)
Appendix Table C11. Design, participant selection and enrollment: Wilm's tumor (MS Word, 47K)
Appendix Table C12. Participant characteristics: Treatment, Wilm's tumor (MS Word, 46K)
Appendix Table C13. Participant characteristics: Comparator, Wilm's tumor (MS Word, 44K)
Appendix Table C14. Treatment characteristics: Wilm's tumor (MS Word, 47K)
Appendix Table C15. Outcome assessment: Treatment, Wilm's tumor (MS Word, 44K)
Appendix Table C16. Outcome assessment: Comparator, Wilm's tumor (MS Word, 43K)
Appendix Table C17. Time to event outcomes: Treatment, Wilm's tumor (MS Word, 48K)
Appendix Table C18. Time to event outcomes: Comparator, Wilm's tumor (MS Word, 43K)
Appendix Table C19. Adverse events: Treatment, Wilm's tumor (MS Word, 45K)
Appendix Table C20. Adverse events: Comparator, Wilm's tumor (MS Word, 43K)
Appendix Table C21. Design, participant selection and enrollment: Rhabdomyosarcoma (MS Word, 48K)
Appendix Table C22. Participant characteristics: Treatment, rhabdomyosarcoma (MS Word, 48K)
Appendix Table C23. Participant characteristics: Comparator, rhabdomyosarcoma (MS Word, 45K)
Appendix Table C24. Treatment characteristics: Rhabdomyosarcoma (MS Word, 51K)
Appendix Table C25. Outcome assessment: Treatment, rhabdomyosarcoma (MS Word, 47K)
Appendix Table C26. Outcome assessment: Comparator, rhabdomyosarcoma (MS Word, 44K)
Appendix Table C27. Time to event outcomes: Treatment, rhabdomyosarcoma (MS Word, 47K)
Appendix Table C28. Time to event outcomes: Comparator, rhabdomyosarcoma (MS Word, 46K)
Appendix Table C29. Adverse events: Treatment, rhabdomyosarcoma (MS Word, 45K)
Appendix Table C30. Adverse events: Comparator, rhabdomyosarcoma (MS Word, 43K)
Appendix Table C31. Design, participant selection and enrollment: Retinoblastoma (MS Word, 46K)
Appendix Table C32. Participant characteristics: Treatment, retinoblastoma (MS Word, 46K)
Appendix Table C33. Participant characteristics: Comparator, retinoblastoma (MS Word, 44K)
Appendix Table C34. Treatment characteristics: Retinoblastoma (MS Word, 47K)
Appendix Table C35. Outcome assessment: Treatment, retinoblastoma (MS Word, 45K)
Appendix Table C36. Outcome assessment: Comparator, retinoblastoma (MS Word, 44K)
Appendix Table C37. Time to event outcomes: Treatment, retinoblastoma (MS Word, 44K)
Appendix Table C38. Time to event outcomes: Comparator, retinoblastoma (MS Word, 43K)
Appendix Table C39. Adverse events: Treatment, retinoblastoma (MS Word, 43K)
Appendix Table C40. Adverse events: Comparator, retinoblastoma (MS Word, 43K)
Appendix Table C41. Design, participant selection and enrollment: Neuroblastoma (MS Word, 45K)
Appendix Table C42. Participant characteristics: Treatment, neuroblastoma (MS Word, 44K)
Appendix Table C43. Participant characteristics: Comparator, neuroblastoma (MS Word, 42K)
Appendix Table C44. Treatment characteristics: Neuroblastoma (MS Word, 46K)
Appendix Table C45. Outcome assessment: Treatment, neuroblastoma (MS Word, 43K)
Appendix Table C46. Outcome assessment: Comparator, neuroblastoma (MS Word, 42K)
Appendix Table C47. Time to event outcomes: Treatment, neuroblastoma (MS Word, 44K)
Appendix Table C48. Time to event outcomes: Comparator, neuroblastoma (MS Word, 44K)
Appendix Table C49. Time to event outcomes: Regression modeling, neuroblastoma (MS Word, 43K)
Appendix Table C50. Adverse events: Treatment, neuroblastoma (MS Word, 47K)
Appendix Table C51. Adverse events: Comparator, neuroblastoma (MS Word, 43K)
Appendix Table C52. Design, participant selection and enrollment: Germ cell tumor (MS Word, 43K)
Appendix Table C53. Participant characteristics: Treatment, germ cell tumor (MS Word, 42K)
Appendix Table C54. Participant characteristics: Comparator, germ cell tumor (MS Word, 43K)
Appendix Table C55. Treatment characteristics: Germ cell tumor (MS Word, 44K)
Appendix Table C56. Outcome assessment: Treatment, germ cell tumor (MS Word, 42K)
Appendix Table C57. Outcome assessment: Comparator, germ cell tumor (MS Word, 42K)
Appendix Table C58. Time to event outcomes: Treatment, germ cell tumor (MS Word, 42K)
Appendix Table C59. Time to event outcomes: Comparator, germ cell tumor (MS Word, 42K)
Appendix Table C60. Adverse events: Treatment, germ cell tumor (MS Word, 47K)
Appendix Table C61. Adverse events: Comparator, germ cell tumor (MS Word, 44K)
Appendix Table C62. Design, participant selection and enrollment: Embryonal tumors (MS Word, 44K)
Appendix Table C63. Participant characteristics: Treatment, embryonal tumors (MS Word, 44K)
Appendix Table C64. Participant characteristics: Comparator, embryonal tumors (MS Word, 42K)
Appendix Table C65. Treatment characteristics: Embryonal tumors (MS Word, 44K)
Appendix Table C66. Outcome assessment: Treatment, embryonal tumors (MS Word, 43K)
Appendix Table C67. Outcome assessment: Comparator, embryonal tumors (MS Word, 42K)
Appendix Table C68. Time to event outcomes: Treatment, embryonal tumors (MS Word, 44K)
Appendix Table C69. Time to event outcomes: Comparator, embryonal tumors (MS Word, 42K)
Appendix Table C70. Quality of life: Embryonal tumors (MS Word, 42K)
Appendix Table C71. Adverse events: Treatment, embryonal tumors (MS Word, 47K)
Appendix Table C72. Adverse events: Comparator, embryonal tumors (MS Word, 43K)
Appendix Table C73. Design, participant selection and enrollment: Glial tumors (MS Word, 51K)
Appendix Table C74. Participant characteristics: Treatment, glial tumors (MS Word, 49K)
Appendix Table C75. Participant characteristics: Comparator, glial tumors (MS Word, 48K)
Appendix Table C76. Treatment characteristics: Glial tumors (MS Word, 57K)
Appendix Table C77. Outcome assessment: Treatment, glial tumors (MS Word, 45K)
Appendix Table C78. Outcome assessment: Comparator, glial tumors (MS Word, 45K)
Appendix Table C79. Time to event outcomes: Treatment, glial tumors OS (MS Word, 56K)
Appendix Table C80. Time to event outcomes: Comparator, glial tumors OS (MS Word, 48K)
Appendix Table C81. Time to event outcomes: Comparator, glial tumors PFS (MS Word, 49K)
Appendix Table C82. Neurological outcomes : Glial tumors (MS Word, 43K)
Appendix Table C83. Adverse events: Treatment, glial tumors (MS Word, 47K)
Appendix Table C84. Adverse events: Comparator, glial tumors (MS Word, 44K)
Appendix Table C85. Design, participant selection and enrollment: Inherited metabolic diseases (MS Word, 54K)
Appendix Table C86. Participant characteristics: Treatment, inherited metabolic diseases (MS Word, 49K)
Appendix Table C87. Participant characteristics: Comparator, inherited metabolic diseases (MS Word, 47K)
Appendix Table C88. Treatment characteristics: Inherited metabolic diseases (MS Word, 57K)
Appendix Table C89. Outcome assessment: Treatment, inherited metabolic diseases (MS Word, 48K)
Appendix Table C90. Outcome assessment: Comparator, inherited metabolic diseases (MS Word, 46K)
Appendix Table C91. Time to event outcomes: Treatment, inherited metabolic diseases (MS Word, 48K)
Appendix Table C92. Time to event outcomes: Comparator, inherited metabolic diseases (MS Word, 43K)
Appendix Table C93. Neurocognitive/neuropsychological outcomes: Inherited metabolic diseases (MS Word, 75K)
Appendix Table C94. Adverse events: Treatment, inherited metabolic diseases (MS Word, 64K)
Appendix Table C95. Adverse events: Comparator, inherited metabolic diseases (MS Word, 48K)
Appendix Table C96. Design, participant selection and enrollment: Autoimmune disease (MS Word, 50K)
Appendix Table C97. Participant characteristics: Treatment, autoimmune disease (MS Word, 48K)
Appendix Table C98. Participant characteristics: Comparator, autoimmune disease (MS Word, 43K)
Appendix Table C99. Treatment characteristics: Autoimmune disease (MS Word, 54K)
Appendix Table C100. Outcome assessment: Treatment, autoimmune disease (MS Word, 50K)
Appendix Table C101. Outcome assessment: Comparator, autoimmune disease (MS Word, 42K)
Appendix Table C102. Time to event outcomes: Treatment, autoimmune disease (MS Word, 50K)
Appendix Table C103. Time to event outcomes: Comparator, autoimmune disease (MS Word, 42K)
- Systematic Review Data Abstraction - Hematopoietic Stem-Cell Transplantation in ...Systematic Review Data Abstraction - Hematopoietic Stem-Cell Transplantation in the Pediatric Population
- Mannosyltransferase [Caenorhabditis elegans]Mannosyltransferase [Caenorhabditis elegans]gi|392889908|ref|NP_001254097.1|Protein
- Caenorhabditis elegans HECT-type E3 ubiquitin transferase (eel-1), partial mRNACaenorhabditis elegans HECT-type E3 ubiquitin transferase (eel-1), partial mRNAgi|1972266395|ref|NM_001307537.4|Nucleotide
- UDP-3-O-acyl-N-acetylglucosamine deacetylase [Thiohalobacter sp. IOR34]UDP-3-O-acyl-N-acetylglucosamine deacetylase [Thiohalobacter sp. IOR34]gi|2532424829|ref|WP_289930610.1|Protein
- SAMN12158268 (1)SRA
Your browsing activity is empty.
Activity recording is turned off.
See more...